Guselkumab

Introduction Overview

Generic Name

guselkumab

Brand Name

Tremfya

Dosage Form

Injection (Tremfya Pen, Prefilled syringe, One-Press Injector), Intravenous infusion (single dose vial)

Drug Class

Interleukin inhibitors

Pharmacokinetics

Absorption:
Guselkumab, the active ingredient in Tremfya, is administered primarily via subcutaneous injection or intravenous infusion depending on treatment phase and condition. Following subcutaneous administration, absorption is relatively slow, with bioavailability estimated at approximately 50-70%, consistent with monoclonal antibody pharmacokinetics. Peak serum concentrations are typically achieved within 5 to 7 days post-dose, indicating gradual systemic uptake from the injection site. The absorption rate can be influenced by factors including injection site blood flow, administration technique, and patient-specific variables such as skin thickness and local tissue conditions. Intravenous administration bypasses absorption processes, delivering drug directly into systemic circulation.

Distribution:
Once in systemic circulation, guselkumab distributes primarily within the vascular and interstitial spaces, characteristic of large protein molecules. The volume of distribution for guselkumab is relatively low, reflective of limited extravascular tissue penetration due to its large molecular size (~143 kDa IgG1 monoclonal antibody). Monoclonal antibodies like guselkumab do not significantly cross cellular membranes or the blood-brain barrier under physiological conditions. The distribution is influenced by binding affinity to its target, the IL-23 p19 subunit, which may modulate tissue localization, particularly in inflamed tissues where IL-23 expression is elevated.

Metabolism:
Guselkumab undergoes catabolism via proteolytic enzymes distributed throughout the reticuloendothelial system, similar to other monoclonal antibodies. It is metabolized into small peptides and amino acids, which are reutilized or excreted. This metabolic pathway is non-specific and does not involve cytochrome P450 enzymes or other hepatic drug metabolizing enzymes, minimizing potential drug-drug interactions based on metabolism. The lack of hepatic metabolism means the drug's clearance is not significantly affected by liver function, although clinical data on patients with hepatic impairment is limited.

Elimination:
The elimination of guselkumab occurs via nonspecific catabolism with an estimated terminal half-life of approximately 15 to 18 days, supporting dosing intervals ranging from every 4 to 8 weeks. The clearance rate is consistent with monoclonal antibody therapeutics, depending on factors such as body weight, target-mediated drug disposition, and immunogenicity. Renal excretion is negligible due to the drug's large size. Formation of anti-drug antibodies can potentially affect clearance by modifying the drug's elimination rate. Overall, the pharmacokinetic profile allows convenient dosing schedules suited for chronic inflammatory conditions treated with Tremfya.

Dosage Forms

Available Dosage Forms:
Tremfya is formulated for subcutaneous injection and intravenous infusion. The available dosage forms include:
- One-Press patient-controlled injector single-dose 100 mg/mL injection
- Tremfya Pen single-dose prefilled pen 200 mg/2 mL (100 mg/mL)
- Prefilled syringe single-dose 100 mg/mL
- Prefilled syringe single-dose 200 mg/2 mL (100 mg/mL)
- Single-dose vial for intravenous infusion 200 mg/20 mL (10 mg/mL)

Dosages for Adults and Adolescents:
- Plaque Psoriasis and Psoriatic Arthritis: 100 mg subcutaneous injection at Week 0, Week 4, then every 8 weeks for maintenance.
- Crohn's Disease Induction: 200 mg IV infusion at Weeks 0, 4, and 8, or 400 mg SC injection at Weeks 0, 4, and 8.
- Crohn's Disease Maintenance: 100 mg SC at Week 16 and every 8 weeks thereafter or 200 mg SC at Week 12 and every 4 weeks thereafter.
- Ulcerative Colitis Induction: 200 mg IV infusion at Weeks 0, 4, and 8.
- Ulcerative Colitis Maintenance: 100 mg SC at Week 16 and every 8 weeks or 200 mg SC at Week 12 and every 4 weeks.

Specific Patient Populations:
- Self-administration is authorized for maintenance subcutaneous injections after initial induction treatment under healthcare professional supervision.
- Intravenous infusions must be administered by healthcare providers during induction phases in Crohn's disease and ulcerative colitis.
- Dose adjustments and frequency depend on specific disease indication, severity, and patient's treatment response.
- No specific dosing modifications have been established for pediatric populations or those with renal/hepatic impairment in the available data.

These detailed dosage forms and regimens reflect flexible administration routes tailored to the autoimmune condition and patient clinical status for optimal efficacy and safety.

Mechanism Of Action

Tremfya’s active ingredient, guselkumab, is a fully human monoclonal antibody that exerts its pharmacologic effect by selectively targeting the p19 subunit of interleukin-23 (IL-23), a pro-inflammatory cytokine integral to the pathogenesis of multiple immune-mediated inflammatory diseases.

IL-23 plays a pivotal role in the differentiation, expansion, and survival of Th17 cells, a subset of T-helper lymphocytes that produce IL-17 and other inflammatory mediators, perpetuating chronic inflammation in conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. By binding the p19 subunit, guselkumab disrupts the interaction of IL-23 with its receptor on immune cells, effectively inhibiting the downstream signaling pathways responsible for inflammatory cytokine production.

This targeted blockade leads to modulation of the immune system, dampening the aberrant inflammatory responses without broad immunosuppression. Clinical studies have demonstrated that IL-23 inhibition reduces skin plaques, joint inflammation, and gastrointestinal symptoms by normalizing immune cell activity and decreasing recruitment of inflammatory cells to affected tissues.

Compared to other biologics like IL-17 inhibitors or TNF-alpha blockers, guselkumab offers a highly specific mechanism with a favorable efficacy and safety profile by focusing on an upstream cytokine in the inflammatory cascade. Research has confirmed that selective IL-23 antagonism by guselkumab results in sustained disease control and improved quality of life for patients suffering from these chronic autoimmune diseases.

Pharmacological Actions

Selective inhibition of interleukin-23 (IL-23) activity by binding to its p19 subunit.
Downregulation of pro-inflammatory Th17 cell development and function.
Reduction of inflammatory cytokine production, including IL-17 and IL-22.
Modulation of immune responses involved in autoimmune pathogenesis.
Suppression of chronic inflammation in skin, joint, and gastrointestinal tissues.
Improvement in immune-mediated inflammatory disease symptoms and progression.
Lack of broad immunosuppression minimizes risk of systemic infections compared to conventional immunomodulators.
Linear pharmacokinetics characteristic of monoclonal antibodies with prolonged half-life enabling infrequent dosing.

Therapeutic Or Clinical Uses

Treatment of moderate-to-severe plaque psoriasis in adult patients.
Management of active psoriatic arthritis in adults, alone or in combination with cDMARDs.
Induction and maintenance therapy for moderately to severely active Crohn’s disease.
Induction and maintenance treatment of moderately to severely active ulcerative colitis.
Reduction of skin lesions, joint inflammation, and gastrointestinal symptoms related to autoimmune diseases.
Patients unsuitable for or inadequately responsive to traditional systemic therapies or phototherapy.
Offered as a biologic targeted therapy with improved safety profiles compared to broad immunosuppressants.
Self-administration enabled for maintenance therapy facilitating outpatient management.

Side Or Adverse Effects

Infections occurring in approximately 23% of patients; includes bacterial, viral, fungal infections.
Upper respiratory tract infections reported in 14.3% of patients.
Headache, affecting approximately 4.6% of patients during clinical trials.
Injection site reactions including pain, itching, swelling, redness, or bruising in 4.5% of patients.
Joint pain reported in 2.7% of cases.
Elevation of liver enzymes in 2.6%, necessitating monitoring for hepatotoxicity.
Diarrhea and gastroenteritis presenting in 1.3-1.6% of patients.
Fungal skin infections and herpes simplex infections each reported in approximately 1.1% of patients.
Serious hypersensitivity reactions including anaphylaxis, facial swelling, and rash reported rarely.
Potential for increased risk of non-melanoma skin cancers compared to some other biologics.
Possible immunosuppression leading to increased susceptibility to infections.
Injection discomfort or localized allergic reactions.
Rare reports of liver injury requiring treatment interruption and monitoring.
Headache and fatigue associated with initial dosing phases.
Gastrointestinal adverse effects, particularly in patients treated for Crohn’s disease and ulcerative colitis.

Precautions

Assess patients for active or latent infections, including tuberculosis, prior to initiation.
Ensure vaccinations are up-to-date; avoid live vaccines during treatment.
Monitor for signs of systemic infection throughout therapy.
Exercise caution in patients with chronic or recurrent infections.
Monitor liver function tests regularly to detect hepatotoxicity, especially in Crohn’s disease and ulcerative colitis patients.
Discontinue if severe hypersensitivity or allergic reactions occur.
Evaluate pregnancy status and counsel regarding unknown fetal risk.
Not established for use in pediatric populations; use with caution in elderly patients.
Avoid injection into psoriatic lesions or compromised skin to reduce local adverse effects.
Maintain refrigeration and proper handling to preserve drug stability and efficacy.
Proper patient education on self-injection technique and disposal of sharps to prevent injury.
Monitor for development of anti-drug antibodies potentially reducing treatment efficacy.
Inform patients about signs and symptoms of infection and hypersensitivity.
Consider immunization history and risk-benefit in immunocompromised individuals.
Encourage enrollment in pregnancy registries when applicable for safety data collection.

Warnings

Risk of serious infections due to immunosuppressive effects; monitor closely.
Hypersensitivity reactions including anaphylaxis and angioedema have been reported.
Potential for drug-induced liver injury necessitates baseline and periodic hepatic monitoring.
Concomitant use with other immunosuppressants may increase infection risk.
Avoid live vaccines during and immediately after treatment due to diminished vaccine efficacy and enhanced infection risk.
Not recommended in patients with active tuberculosis or severe infections.
Patients should be counseled regarding the risk of malignancy including non-melanoma skin cancers.
Use caution in patients with pre-existing immune disorders or compromised immunity.
Abrupt discontinuation of therapy may result in disease flare-ups.
Potential for immune-related adverse events, including hypersensitivity and infusion reactions, especially with intravenous administration.
Unknown long-term safety profile; continuous monitoring recommended.
Pregnancy safety has not been established; weigh benefits against potential risks.
Safety in breastfeeding patients is unknown; exercise caution.
Avoid administration in areas with active infections or ulcers.
Monitor for worsening of infection symptoms despite therapy.

Contraindication

Known hypersensitivity to guselkumab or any of the product's excipients, including polysorbate 80.
Active severe infections such as tuberculosis or systemic fungal infections.
Patients with known hypersensitivity reactions to monoclonal antibodies.
History of serious allergic reactions to previous biologic therapies targeting interleukins.
Concomitant use with live vaccines due to potential immunosuppressive effect.
Use in patients with active malignancy without thorough evaluation and risk assessment.
Contraindicated if systemic infections cannot be effectively controlled prior to treatment initiation.
Avoid in patients with unstable or uncontrolled chronic infections.
Patients with acute hypersensitivity reactions during initial treatment should discontinue therapy.
Patients with known severe hepatic impairment due to lack of safety data.
Known allergy to any components within the medication formulation, including inactive ingredients.
Pregnant women unless potential benefit justifies the potential risk.
Pediatric patients below approved age limits due to safety and efficacy not established.
Use contraindicated in patients who cannot comply with monitoring and administration requirements.
Patients unwilling or unable to appropriately self-administer injections in maintenance phases.

Drug Interactions

Potential interaction with CYP450 substrates as inflammation suppression may normalize CYP450 enzyme activity, altering drug metabolism.
Monitor therapeutic effects or drug concentration of CYP450 substrates with narrow therapeutic indices upon initiation or discontinuation of Tremfya.
No direct pharmacokinetic interactions observed with commonly co-administered immunosuppressants such as methotrexate.
Avoid live vaccines during treatment to prevent reduced vaccine efficacy and increased infection risk.
No significant interaction with other biologics targeting different cytokines documented; however, concurrent use not generally recommended.
Co-administration with TNF-alpha inhibitors has not been systematically studied and may increase immunosuppression.
Concurrent immunosuppressive therapy may increase risk of serious infections.
No known interactions with commonly used over-the-counter medications, vitamins, or herbal supplements.
No significant effects on renal or hepatic clearance pathways, minimizing metabolism-based interactions.
Potential additive immunosuppression with corticosteroids requires clinical monitoring.
Use with caution in patients receiving multiple immunomodulatory agents.
Limited data on interactions with experimental or investigational drugs.
No known food or alcohol interactions affecting therapy.
Drug interaction profile is favorable due to monoclonal antibody nature and proteolytic metabolism.
Healthcare providers should consult current prescribing information for updates on clinically relevant interactions.

Preparations Of The Drug

One-Press patient-controlled injector single-dose 100 mg/mL injection for subcutaneous use.
Tremfya Pen single-dose prefilled pen 200 mg/2 mL (100 mg/mL) designed for easy self-administration.
Prefilled syringe single-dose 100 mg/mL for subcutaneous injection.
Prefilled syringe single-dose 200 mg/2 mL (100 mg/mL) serving patients requiring higher dose volumes.
Single-dose vial 200 mg/20 mL (10 mg/mL) for intravenous infusion used during induction phases of therapy.
Inactive ingredients include L-histidine, L-histidine monohydrochloride monohydrate, polysorbate 80, sucrose, with water for injection ensuring product stability.
Formulations are latex-free to minimize risk of allergic reactions.
Storage recommended under refrigeration (2°C to 8°C), protected from light and freezing.
All preparations are for single-use only; proper disposal of needles and syringes is mandatory.
Instructions for use accompany all forms to educate patients and healthcare providers on safe administration.
Prefilled devices support adherence and reduce administration errors in outpatient settings.
Infusion preparations require appropriate dilution and administration protocols in clinical settings.
Careful handling and transport to maintain cold chain and drug potency.
Packaging ensures sterility and stability during shelf-life.
Each dosage form supports tailored therapeutic regimens across multiple indications.